Lipoxygenase inhibitors have been reported to have a therapeutic effect in psoriasis. Mesalazine, a lipoxygenase inhibitor, similar to sulfasalazine was tried in psoriasis. Patients with moderate to severe psoriasis were treated with mesalazine in a dose of 400 mg thrice a day for 8 weeks. Patients were assessed for disease activity at the start of therapy, at 4 weeks and at 8 weeks using the psoriasis area severity index (PASI). Twenty-one patients (18 males and 3 females) of stable plaque psoriasis with a mean age of 42.3 years were included in the study. Duration of disease ranged from 3 months to 30 years. Mean body surface area involved was 36.3%. Of 19 patients who completed the study, 7 (36.8%) had >40% decline in PASI. Two patients did not respond to therapy. Mean baseline PASI decreased from 16.2 to 13.2 at 4 weeks and 10.1 at ZHHNV S %RWK WKH YDOXHV ZHUH VWDWLVWLFDOO\ VLJQL¿FDQW 0HVDOD]LQH FDQ SURYH WR EH D VLJQL¿FDQW DGGLWLRQ RU DGMXQFW WR the systemic therapies available for the treatment of psoriasis.
INTRODUCTION
3VRULDVLV LV D JHQHWLFDOO\ GHWHUPLQHG FKURQLF LQÀDPPDWRU\ skin disorder that still eludes cure. Both conventional and systemic modalities used in the treatment of psoriasis have their limitations like hepatotoxicity associated with methotrexate, mutagenic potential of PUVA and skeletal and teratogenic effects of retinoids. The scope for newer safe and effective systemic therapies in psoriasis is hence immense. Elevated levels of arachidonic acid 1 along with increased 5 and 12-lipoxygenase activity resulting in increased production of eicosanoid mediators of LQÀDPPDWLRQ /7% KDYH EHHQ IRXQG LQ SVRULDWLF VNLQ 2 6XOIDVDOD]LQHD SRWHQW OLSR[\JHQDVH LQKLELWRU KDV EHHQ IRXQG WR EH WKHUDSHXWLFDOO\ HIIHFWLYH LQ ERWK SVRULDVLV DQG psoriatic arthritis. [3] [4] [5] [6] [7] 
MATERIALS AND METHODS
Adult patients with moderate to severe plaque-type psoriasis for at least 6 months which involved at least 10% of the ERG\ ¶V VXUIDFH DUHD ZHUH HQUROOHG LQ WKH VWXG\ 7KH SDWLHQWV were candidates for systemic therapy or phototherapy and FRXOG QRW EH PDQDJHG E\ WRSLFDO WKHUDS\ 3DWLHQWV ZLWK clinically relevant gastrointestinal, hepatic or renal disorders, DQG WKRVH ZLWK XQVWDEOH PHWDEROLF RU HQGRFULQH GLVRUGHUV were excluded, as were those with systemic or generalized infections, or a history of malignancy. The patients had not received other systemic disease modifying drugs or phototherapy within 28 days, or topical therapy within GD\V RI VWDUWLQJ PHVDOD]LQH :RPHQ RI FKLOGEHDULQJ potential had to have a negative urine pregnancy test at screening, and agree to use two forms of contraception throughout the stud\ 0HQ DJUHHG WR XVH EDUULHU FRQWUDFHSWLRQ while on study medication. All patients provided written LQIRUPHG FRQVHQW Eefore entering the study, and the protocol ZDV DSSURYHG E\ WKH GHSDUWPHQW UHYLHZ ERDUG
The study consisted of three phases: A 28-day screening phase, 8 weeks treatment period where patients received PHVDOD]LQH PJ WLG DQG D ZHHNV REVHUYDWLRQDO IROORZXS SKDVH WR DVVHVV IRU SVRULDVLV UHODSVH DQG ÀDUH The patients were instructed not to use any additional medications for psoriasis during the treatment phase except antihistamines, nonmedicated emollients and shampoos.
The patients were recruited over a period of 2 years and all of them underwent a pretreatment evaluation The therapeutic result seen with mesalazine in our VWXG\ LV XQGHQLDEO\ PRGHVW EXW LW LV FRPSDUDEOH WR WKDW seen with newer expensive drugs like mycophenolate, tacrolimus and pimecrolimus which are also not free from side effects. 10,11 6LQFH WKH SDWLHQW QXPEHU ZDV OHVV LW LV QRW SRVVLEOH IRU XV WR FRPPHQW DERXW DQ\ GH¿QLWH SUHGLFWRUV of outcome. Mesalazine is an immunomodulatory and an DQWLLQÀDPPDWRU\ GUXJ LQKLELWLQJ LQWHUOHXNLQ UHOHDVH DQG LQÀDPPDWRU\ FHOO FKHPRWD[LV ZLWK FRPSDUDWLYHO\ IHZ VHULRXV VLGH HIIHFWV :H REVHUYHG WKDW PHVDOD]LQH SURGXFHG a significant reduction in psoriasis severity, at doses RI PJ WLG DQG LW ZDV ZHOO WROHUDWHG +RZHYHU VWXGLHV RI ORQJHU GXUDWLRQ LQ ODUJHU QXPEHU RI SDWLHQWV DUH QHHGHG to fully assess the efficacy and safety of mesalazine in psoriasis.
